Burwood, Australia

Jeremy Robert Arthur Paull

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Starpharma Pty Limited. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremy Robert Arthur Paull. Retrieved from https://idiyas.com/inventor/jeremy-robert-arthur-paull

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.7

ph-index = 1


Location History:

  • Burwood, AU (2015 - 2022)
  • Abbotsford, AU (2024)

Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Inventor Jeremy Robert Arthur Paull: Innovations in Therapeutic Dendrimers

Introduction

Jeremy Robert Arthur Paull, an esteemed inventor based in Burwood, Australia, has made significant contributions to the field of pharmaceutical innovations. With a total of four patents to his name, Paull focuses primarily on dendrimer technology and its applications in treating various medical conditions, particularly cancers and eye infections.

Latest Patents

Among his latest inventions, Paull developed a pioneering therapeutic dendrimer. This innovative structure comprises a core unit and five generations of building units, consisting of lysine residues or their analogues. The dendrimer features terminal groups that consist of a cabazitazel residue linked to a diglycolyl group, alongside second terminal groups containing a PEG group. This design allows for pharmaceutical compositions that leverage these dendrimers in combating disorders such as cancers. Furthermore, Paull's patent also includes methods for manufacturing these dendrimers and their intermediates.

In addition, Paull has patented a method for treating or preventing infections in the eye. This method involves topically administering a macromolecule or a pharmaceutically acceptable salt that incorporates a dendrimer with 1 to 8 generations. This dendrimer is characterized by its moieties containing sulfonic acid or sulfonate groups attached to the outermost generation's surface. Such compositions are essential for addressing microbial infections effectively.

Career Highlights

Jeremy Robert Arthur Paull works at Starpharma Pty Limited, a company renowned for its focus on dendrimer technologies and a pioneer in this innovative field. His work continues to push the boundaries of pharmaceutical development, bringing novel solutions to critical health challenges.

Collaborations

Throughout his career, Paull has collaborated with talented professionals, including Jacinth Kincaid Fairley and Colin Paul Barrett. These partnerships exemplify his commitment to advancing research and innovation within the pharmaceutical industry, ensuring that his inventions reach their full potential in practical applications.

Conclusion

As an inventor, Jeremy Robert Arthur Paull exemplifies how innovative thinking can transform therapeutic approaches to significant health issues. With his work at Starpharma Pty Limited and his groundbreaking patents, Paull continues to impact the fields of medicine and pharmaceutical development profoundly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…